Le 3-4 décembre 2023, le Comité consultatif national sur les annexes de médicaments (CCNAM) a proposé les recommandations provisoires suivantes (disponibles qu’en anglais) :

• Acetaminophen and ibuprofen in oral, fixed-dose combinations, in package sizes containing 20,000 mg or less of acetaminophen and 6,000 mg or less of ibuprofen, remain in Schedule III and

• Acetaminophen and ibuprofen in oral, fixed-dose combinations, in package sizes containing either more than 20,000 mg of acetaminophen or more than 6,000 mg of ibuprofen, remain in Schedule II

• Brimonidine tartrate ophthalmic solution in concentrations up to and including 0.025%, used for the relief of redness of the eye due to minor eye irritations caused by environmental allergies, dryness and fatigue for adults of 18 years and older be granted Unscheduled status

• Brimonidine or its salts, except when sold as brimonidine tartrate ophthalmic solution in concentrations up to and including 0.025%, used for the relief of redness of the eye due to minor eye irritations caused by environmental allergies, dryness and fatigue for adults of 18 years and older, will remain in Schedule I (as per the Prescription Drug List)

Ces recommandations ont été finalisées le 23 janvier 2024. Le conseil d’administration de l’ANORP a approuvé les recommandations provisoires en tenant compte des commentaires reçus au cours de la période de consultation de 30 jours. Les Annexes nationales de médicaments seront révisées en conséquence.